Sex-specific amplification of IKr-blocker-induced action potential prolongation by reduced female IKs repolarization reserve: a computational study using the O'Hara-Rudy human ventricular model

Using a computational model of human ventricular cardiomyocytes, this study demonstrates that a 45% reduction in female IKs conductance significantly amplifies the action potential prolongation caused by IKr blockade compared to males, providing a quantitative ionic basis for the higher susceptibility of women to drug-induced Torsades de Pointes.

The Gist

Imagine your heart is a high-performance race car engine. For this engine to run safely, it needs to speed up and slow down with perfect rhythm. The "slowing down" part is crucial; if the engine takes too long to reset before the next burst of power, the whole system can sputter and fail. In the heart, this "reset" is called repolarization.

This paper explores why women's hearts seem to be more sensitive to certain drugs that mess with this reset button, leading to a dangerous heart rhythm problem called Torsades de Pointes (TdP). While we know women get this condition about twice as often as men, the exact "mechanical" reason has been a bit of a mystery.

The Two Brakes
Think of the heart's electrical system as having two different types of brakes to help it slow down and reset:

1. The Primary Brake (IKr): This is the main brake. Many heart medications accidentally press too hard on this one, which is dangerous.
2. The Backup Brake (IKs): This is the safety net. If the primary brake is pressed too hard, the backup brake kicks in to help the heart recover safely.

The Gender Difference
The researchers discovered a key difference between male and female heart cells: Women have a weaker backup brake. Specifically, the conductance (or strength) of the IKs current is about 45% lower in female heart cells compared to male cells.

The Computer Simulation
To test how this plays out, the scientists built a super-detailed digital model of a human heart cell (using the O'Hara-Rudy model) inside a computer. They created two versions:

• The Male Model: With a standard, strong backup brake.
• The Female Model: With the 45% weaker backup brake.

They then simulated what happens when you gradually press harder and harder on the "Primary Brake" (simulating the effect of a drug) at different heart rates (fast, normal, and slow).

What They Found
The results showed a fascinating and dangerous pattern:

• At the start: Even without any drugs, the female model's heart took just a tiny bit longer to reset than the male's. It was a small difference, like a car taking an extra second to stop.
• The Snowball Effect: As they increased the drug pressure (blocking the primary brake), the difference didn't just stay the same—it exploded.
  • At a moderate level of drug block, the female heart took 13 times longer to reset than the male heart.
  • At a slow heart rate (which is when the heart relies most on its backup systems), the gap became massive. At high drug levels, the female heart took nearly 200 milliseconds longer to reset than the male heart.
• The Tipping Point: The female heart hit the "danger zone" (where the reset takes too long and becomes unstable) with 5% less drug than the male heart. In other words, the female heart's safety net gave out much sooner.
• Shape Matters: The female heart's electrical signal also became more "triangular" (stretched out and uneven), which is a known warning sign of instability.

The Bottom Line
The study concludes that because women naturally have a weaker "backup brake" (IKs), their hearts have less "repolarization reserve" to handle drugs that block the "primary brake" (IKr). When that primary brake is pressed by medication, the female heart's weaker backup system can't compensate as well as the male heart's, causing the electrical reset to stretch out dangerously.

This computer study suggests that the reason women are more susceptible to these drug-induced heart issues is simply that their built-in safety margin is smaller to begin with.

Technical Summary

Technical Summary: Sex-Specific Amplification of IKr-Blocker-Induced Action Potential Prolongation

Problem Statement
Women experience drug-induced Torsades de Pointes (TdP) at approximately twice the rate of men across more than 50 classes of QT-prolonging drugs. Despite this well-documented clinical disparity, the quantitative ionic basis explaining why female cardiomyocytes are more susceptible remains incompletely characterized. A primary physiological difference is the reduction of the slow delayed rectifier current ($I_{Ks}$) by approximately 45% in female human ventricular cardiomyocytes compared to males. This reduction theoretically diminishes the "repolarization reserve" available to compensate for pharmacological blockade of the rapid delayed rectifier current ($I_{Kr}$), yet the specific dynamics of this interaction under varying pacing rates require rigorous computational validation.

Methodology
To investigate this mechanism, the authors implemented the O'Hara-Rudy (ORd) 2011 undiseased human ventricular epicardial action potential model within a Python environment. The model was parameterized to reflect sex-specific differences based on the most robustly established human ionic variance: a 45% reduction in $I_{Ks}$ conductance ($G_{Ks}$) for the female variant, consistent with data from Kurokawa et al. (2016).

Simulations were conducted to assess the impact of graded $I_{Kr}$ blockade (ranging from 0% to 95% in 5% increments) across three physiologically relevant pacing rates: 2 Hz, 1 Hz, and 0.5 Hz. Each simulation included a 60-beat warm-up period to ensure the system approached electrophysiological steady state. The numerical integration utilized SciPy's Radau solver with tight tolerances ($rtol = 10^{-9}$, $atol = 10^{-9}$) and a Numba-JIT-compiled right-hand side to ensure computational efficiency.

Key metrics quantified included:

• Action Potential Duration at 90% repolarization ($APD_{90}$): To measure overall prolongation.
• Triangulation: Calculated as $APD_{90} - APD_{30}$, serving as a marker for repolarization instability.
• Repolarization Failure: Defined conservatively as either an $APD_{90}$ exceeding 500 ms (informed by clinical QTc safety thresholds) or a failure to repolarize within the cycle length.

Key Results
The study demonstrated that a 45% reduction in $I_{Ks}$ conductance is sufficient to produce measurably greater $APD_{90}$ prolongation under $I_{Kr}$ blockade across all tested pacing rates.

• Baseline Differences: At 0% block, the female model exhibited longer baseline $APD_{90}$ than the male model at all rates (+2.8 ms at 2 Hz; +4.6 ms at 1 Hz; +4.6 ms at 0.5 Hz).
• Non-Linear Amplification: Under progressive $I_{Kr}$ blockade, the absolute sex difference in $APD_{90}$ amplified non-linearly. At 1 Hz pacing with 85% block, the female $APD_{90}$ exceeded the male by 60.4 ms, representing a 13-fold amplification compared to the baseline difference of 4.6 ms.
• Rate Dependence: The sex gap was most pronounced at slow pacing rates. At 0.5 Hz and 85% block, the female $APD_{90}$ reached 1127 ms compared to 939 ms for the male, a difference of +188 ms (20% more prolonged).
• Thresholds and Failure: The critical $APD$ threshold (>500 ms) was reached by female cells at 5 percentage points lower $I_{Kr}$ block than male cells at 1 Hz pacing (55% vs. 60%). Similarly, repolarization failure occurred 5 percentage points earlier in females at 1 Hz (90% vs. 95% block).
• Triangulation: Action potential triangulation was consistently greater in the female model at all block levels and pacing rates, indicating increased repolarization instability.

Significance and Claims
The paper concludes that the reduced $I_{Ks}$ repolarization reserve in females is a sufficient mechanism to explain the non-linear amplification of the sex gap in drug-induced QT prolongation. The findings support the hypothesis that this ionic disparity contributes significantly to the greater female susceptibility to drug-induced TdP. Consequently, the study advocates for the inclusion of sex-specific parameterizations in CiPA-style (Comprehensive in vitro Proarrhythmia Assay) in silico cardiac safety workflows to better predict drug risks.